Jeil Pharm (002620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jeil Pharm (002620) has a cash flow conversion efficiency ratio of 0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩447.08 Million ≈ $302.98K USD) by net assets (₩475.12 Billion ≈ $321.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 002620 market cap overview for the company's overall valuation and market capitalisation.
Jeil Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Jeil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jeil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharm ranked by their cash flow conversion efficiency. Explore 002620 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd
KQ:333430
|
0.030x |
|
Island Pharmaceuticals Ltd
AU:ILA
|
-0.237x |
|
Atrium Real Estate Investment Trust
KLSE:5130
|
0.029x |
|
Ten Ren Tea Co Ltd
TW:1233
|
0.050x |
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
-2.154x |
|
Keum Kang Steel Co. Ltd
KQ:053260
|
-0.014x |
|
Xlife Sciences AG
SW:XLS
|
-0.002x |
|
Amanat Acquisition Corp Class A Ordinary Shares
NASDAQ:AMAN
|
N/A |
Annual Cash Flow Conversion Efficiency for Jeil Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jeil Pharm from 2011 to 2025. View Jeil Pharm stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩469.12 Billion ≈ $317.91 Million |
₩390.26 Million ≈ $264.47K |
0.001x | -91.99% |
| 2024-12-31 | ₩437.40 Billion ≈ $296.42 Million |
₩4.54 Billion ≈ $3.08 Million |
0.010x | +194.59% |
| 2023-12-31 | ₩402.19 Billion ≈ $272.56 Million |
₩-4.42 Billion ≈ $-2.99 Million |
-0.011x | +77.84% |
| 2022-12-31 | ₩419.79 Billion ≈ $284.49 Million |
₩-20.80 Billion ≈ $-14.10 Million |
-0.050x | -284.97% |
| 2021-12-31 | ₩500.31 Billion ≈ $339.06 Million |
₩13.40 Billion ≈ $9.08 Million |
0.027x | +156.50% |
| 2020-12-31 | ₩499.28 Billion ≈ $338.36 Million |
₩-23.67 Billion ≈ $-16.04 Million |
-0.047x | -190.82% |
| 2019-12-31 | ₩483.04 Billion ≈ $327.35 Million |
₩25.22 Billion ≈ $17.09 Million |
0.052x | +996.58% |
| 2018-12-31 | ₩589.58 Billion ≈ $399.55 Million |
₩-3.43 Billion ≈ $-2.33 Million |
-0.006x | -116.75% |
| 2017-12-31 | ₩170.44 Billion ≈ $115.50 Million |
₩5.92 Billion ≈ $4.01 Million |
0.035x | -22.85% |
| 2016-12-31 | ₩252.08 Billion ≈ $170.83 Million |
₩11.36 Billion ≈ $7.70 Million |
0.045x | +296.38% |
| 2015-12-31 | ₩241.39 Billion ≈ $163.59 Million |
₩2.74 Billion ≈ $1.86 Million |
0.011x | +169.58% |
| 2012-12-31 | ₩241.41 Billion ≈ $163.60 Million |
₩-3.94 Billion ≈ $-2.67 Million |
-0.016x | -116.00% |
| 2011-12-31 | ₩231.40 Billion ≈ $156.81 Million |
₩23.63 Billion ≈ $16.01 Million |
0.102x | -- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more